JP2018530582A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530582A5
JP2018530582A5 JP2018519276A JP2018519276A JP2018530582A5 JP 2018530582 A5 JP2018530582 A5 JP 2018530582A5 JP 2018519276 A JP2018519276 A JP 2018519276A JP 2018519276 A JP2018519276 A JP 2018519276A JP 2018530582 A5 JP2018530582 A5 JP 2018530582A5
Authority
JP
Japan
Prior art keywords
substituted
halo
alkyl
compound according
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519276A
Other languages
English (en)
Japanese (ja)
Other versions
JP6843853B2 (ja
JP2018530582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/056716 external-priority patent/WO2017066368A1/en
Publication of JP2018530582A publication Critical patent/JP2018530582A/ja
Publication of JP2018530582A5 publication Critical patent/JP2018530582A5/ja
Application granted granted Critical
Publication of JP6843853B2 publication Critical patent/JP6843853B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519276A 2015-10-14 2016-10-13 選択的nr2bアンタゴニスト Expired - Fee Related JP6843853B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3309/DEL/2015 2015-10-14
IN3309DE2015 2015-10-14
PCT/US2016/056716 WO2017066368A1 (en) 2015-10-14 2016-10-13 Selective nr2b antagonists

Publications (3)

Publication Number Publication Date
JP2018530582A JP2018530582A (ja) 2018-10-18
JP2018530582A5 true JP2018530582A5 (enExample) 2019-11-21
JP6843853B2 JP6843853B2 (ja) 2021-03-17

Family

ID=57208377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018519276A Expired - Fee Related JP6843853B2 (ja) 2015-10-14 2016-10-13 選択的nr2bアンタゴニスト

Country Status (13)

Country Link
US (2) US10501451B2 (enExample)
EP (1) EP3362447B1 (enExample)
JP (1) JP6843853B2 (enExample)
KR (1) KR20180064507A (enExample)
CN (1) CN108368101B (enExample)
AU (1) AU2016340239A1 (enExample)
BR (1) BR112018007181A2 (enExample)
CA (1) CA3001894A1 (enExample)
EA (1) EA201890764A1 (enExample)
ES (1) ES2822830T3 (enExample)
IL (1) IL258611A (enExample)
MX (1) MX2018004257A (enExample)
WO (1) WO2017066368A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018006537A2 (pt) * 2015-10-14 2018-10-16 Bristol-Myers Squibb Company antagonistas seletivos de nr2b
US11104670B2 (en) * 2018-10-17 2021-08-31 Boehringer Ingelheim International Gmbh 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament
CN112888685B (zh) * 2018-10-17 2023-09-22 勃林格殷格翰国际有限公司 4-吡嗪-2-基甲基-吗啉衍生物及其作为药物的用途
JP7093469B2 (ja) * 2018-10-17 2022-06-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 4-ピリジニルメチル-モルホリン誘導体および医薬としてのその使用
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
TW202237103A (zh) * 2020-12-04 2022-10-01 瑞士商諾華公司 用於治療抑鬱症的nr2b-nmda受體nam之劑量方案
CN113620896A (zh) * 2021-08-31 2021-11-09 青岛科技大学 2-(2-氯苯基)甲基-4,4-二甲基-3-异恶唑酮的制备方法
CN116063200A (zh) * 2022-12-12 2023-05-05 华南理工大学 一种异噁唑啉宠物用杀虫剂氟雷拉纳中间体及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US7022728B2 (en) 2001-03-09 2006-04-04 Abbott Laboratories Benzimidazoles that are useful in treating male sexual dysfunction
WO2003035641A1 (en) 2001-10-22 2003-05-01 Shionogi & Co., Ltd. Novel carbamoylpyrrolidone derivative
MXPA05013151A (es) 2003-06-04 2006-03-17 Merck & Co Inc 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
JP2007508288A (ja) 2003-10-08 2007-04-05 ファイザー株式会社 縮合ラクタム化合物
US20070185168A1 (en) * 2004-04-07 2007-08-09 Takai Haruki S Piperidine derivatives
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
US7935706B2 (en) 2006-02-23 2011-05-03 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
CN101815518B (zh) 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂
JP2009067784A (ja) * 2007-08-21 2009-04-02 Shionogi & Co Ltd 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
US9221796B2 (en) * 2014-01-09 2015-12-29 Bristol-Myers Squibb Company Selective NR2B antagonists
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Similar Documents

Publication Publication Date Title
JP2018530582A5 (enExample)
JP2013537203A5 (enExample)
JP2016506960A5 (enExample)
JP2019513778A5 (enExample)
JP2016505614A5 (enExample)
JP2020502092A5 (enExample)
JP2019518766A5 (enExample)
JP2013544846A5 (enExample)
JP2014504646A5 (enExample)
JP2008533191A5 (enExample)
JP2006524660A5 (enExample)
JP2015509534A5 (enExample)
JP2017533968A5 (enExample)
JP2016534134A5 (enExample)
RU2016118768A (ru) Композиции, пригодные для лечения расстройств, связанных с kit
JP2015509535A5 (enExample)
JP2017538773A5 (enExample)
JP2012510502A5 (enExample)
SI2743266T1 (en) Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis
JP2016534063A5 (enExample)
JP2013544860A5 (enExample)
JP2019501130A5 (enExample)
JP2016503797A5 (enExample)
JP2015508092A5 (enExample)
JP2011513410A5 (enExample)